Savage Martin O, Fernandez-Luque Luis, Graham Selina, van Dommelen Paula, Araujo Matheus, de Arriba Antonio, Koledova Ekaterina
Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, London, UK.
Adhera Health Inc., Palo Alto, CA, USA.
Patient Prefer Adherence. 2022 Jul 11;16:1663-1671. doi: 10.2147/PPA.S271453. eCollection 2022.
Pediatric growth hormone (GH) deficiency is a licensed indication for replacement therapy with recombinant human growth hormone (r-hGH). Treatment, consisting of daily subcutaneous injections, extends from the time of diagnosis until cessation of linear growth at completion of puberty. Suboptimal adherence to r-hGH therapy is common and has been well documented to substantially impair the growth response and achievement of the optimal goal which is attainment of adult height within the genetic target range. The causes of poor adherence are complex and include disease-, patient-, doctor-, and treatment-related factors. Interventions for suboptimal adherence are important for a long-term successful outcome and can include both face-to-face and digital strategies. Face-to-face interventions include behavioral change approaches such as motivational interviewing and non-judgmental assessment. Medical and nursing staff require training in these techniques. Digital solutions are rapidly advancing as evidenced by the electronic digital auto-injector device, easypod® (Merck Healthcare KGaA, Darmstadt, Germany), which uses the web-based easypod® connect platform allowing adherence data to be transmitted electronically to healthcare professionals (HCPs), who can then access GH treatment history, enhancing clinical decisions. Over the past 10 years, the multi-national Easypod® Connect Observational Study has reported high levels of adherence (>85%) from up to 40 countries. The easypod® connect system can be supported by a smartphone app, growlink™, which facilitates the interactions between the patients, their care team, and patient support services. HCPs are empowered by new digital techniques, however, the human-digital partnership remains essential for optimal growth management. The pediatric patient on r-hGH therapy will benefit from these innovations to enhance adherence and optimize long-term response.
儿童生长激素(GH)缺乏是重组人生长激素(r-hGH)替代疗法的一个获批适应症。治疗包括每日皮下注射,从诊断时开始,直至青春期结束线性生长停止。对r-hGH治疗的依从性欠佳很常见,且有充分记录表明这会严重损害生长反应以及实现最佳目标,即达到遗传目标范围内的成人身高。依从性差的原因很复杂,包括疾病、患者、医生和治疗相关因素。针对依从性欠佳的干预措施对于长期成功治疗结果很重要,可包括面对面和数字化策略。面对面干预包括行为改变方法,如动机性访谈和无评判性评估。医护人员需要接受这些技术的培训。数字解决方案正在迅速发展,电子数字自动注射器设备easypod®(德国达姆施塔特的默克医疗保健有限公司)就是证明,它使用基于网络的easypod® connect平台,允许将依从性数据以电子方式传输给医疗保健专业人员(HCPs),这些人员随后可以访问生长激素治疗史,从而加强临床决策。在过去10年中,多国的easypod® Connect观察性研究报告了来自多达40个国家的高依从性水平(>85%)。easypod® connect系统可以由智能手机应用程序growlink™提供支持,该应用程序促进患者、他们的护理团队和患者支持服务之间的互动。新的数字技术使HCPs有了更多能力,然而,人机数字伙伴关系对于最佳生长管理仍然至关重要。接受r-hGH治疗的儿科患者将受益于这些创新,以提高依从性并优化长期反应。